Moody's weighs ratings as drug-patent lapses near

(Reuters) - Eli Lilly and Co. , Pfizer Inc. and
Bristol-Myers Squibb Co. are particularly vulnerable to
the downgrades because the top-selling drug of each expires in
that period.




Merck & Co. could also be adversely affected as two
of its important drugs face patent expirations.


Read more at Reuters.com Bonds News